Bob joined Brandon Capital in 2016.
Prior to joining Brandon Capital, Bob worked at Nucleus Network, Australia’s largest clinical trials unit. He was an investigator in over 100 early phase clinical trials, including as PI. He was heavily involved in various aspects of the business, including overseeing its clinical operations, business development and expanding Nucleus Network’s trial capabilities.
During his time at Nucleus Network, he was concurrently appointed as the acting CEO for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through phase 2 clinical trials, and successfully led the Company’s FDA regulatory and IP strategy. The program was subsequently licensed to a specialty pharmaceutical company.
Bob obtained his MD from The University of Melbourne, and subsequently undertook his surgical residency in some of Australia’s top leading academic hospitals, including the Royal Melbourne Hospital and Royal North Shore Hospital.
Bob is currently a director of Glyscend, and a board observer of Entact Bio. He is also a graduate of the Australian Institute of Company Directors and lectures at The University of Melbourne.